Most Popular

M & A Deals | M & A League Table | Real Assets | Sector Events |  Private Capital Conference

Saudi’s Chronic Kidney Disease Care & National Dialysis Services PPP Programme – one of the Kingdom’s most compelling healthcare investment opportunities

Analysis Nick Herbert -
Saudi Arabia's healthcare sector is undergoing one of the most significant transformations in its history. Driven by Vision 2030, the Kingdom continues to increase private sector participation across healthcare delivery, infrastructure, and clinical services, creating new opportunities for operators, investors, consortium partners, and healthcare infrastructure providers, says Mansoor Ahmed,...

Switzerland: Samsung Biologics to acquire PolyPeptide for US$1.8bn

M&A Nick Herbert -
Listed South Korean CDMO, Samsung Biologics, is acquiring all shares in SIX-listed PolyPeptide, a specialised CDMO for peptide-based active pharmaceutical ingredients, for CHF44.31 per share. The offer values PolyPeptide's equity at approximately CHF1.46bn (US$1.8bn). “This acquisition reinforces our long-term growth strategy by not only broadening our service portfolio with modality expansion into peptides including GLP-1, but by also boosting our geographic reach and proximity further within the US, Europe, and India,” said John Rim, chairman and CEO of Samsung Biologics. The offer price represents a 40% premium to the CHF31.65 share...